Therapeutic challenges in peripheral T-cell lymphoma
Abstract Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01904-w |
| _version_ | 1797363561114107904 |
|---|---|
| author | Yunpeng Luan Xiang Li Yunqi Luan Junyu Luo Qinzuo Dong Shili Ye Yuejin Li Yanmei Li Lu Jia Jun Yang Dong-Hua Yang |
| author_facet | Yunpeng Luan Xiang Li Yunqi Luan Junyu Luo Qinzuo Dong Shili Ye Yuejin Li Yanmei Li Lu Jia Jun Yang Dong-Hua Yang |
| author_sort | Yunpeng Luan |
| collection | DOAJ |
| description | Abstract Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions. |
| first_indexed | 2024-03-08T16:23:02Z |
| format | Article |
| id | doaj.art-19a8bd36d134494587114d1d9e55d650 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-03-08T16:23:02Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-19a8bd36d134494587114d1d9e55d6502024-01-07T12:14:25ZengBMCMolecular Cancer1476-45982024-01-0123111810.1186/s12943-023-01904-wTherapeutic challenges in peripheral T-cell lymphomaYunpeng Luan0Xiang Li1Yunqi Luan2Junyu Luo3Qinzuo Dong4Shili Ye5Yuejin Li6Yanmei Li7Lu Jia8Jun Yang9Dong-Hua Yang10The First Affiliated Hospital of Yunnan University of Traditional Chinese MedicineThe First Affiliated Hospital of Yunnan University of Traditional Chinese MedicineNMPA Key Laboratory for Safety Research and Evaluation of Innovative Drugs, Beijing Key Laboratory of Analysis and Evaluation On Chinese Medicine, Beijing Institute for Drug ControlThe First Affiliated Hospital of Yunnan University of Traditional Chinese MedicineThe First Affiliated Hospital of Yunnan University of Traditional Chinese MedicineKey Laboratory for Forest Resources Conservation and Utilization in the Southwest Mountains of China, Ministry of Education, Southwest Forestry UniversityThe Affiliated Hospital of Kunming University of Science and TechnologyKey Laboratory for Forest Resources Conservation and Utilization in the Southwest Mountains of China, Ministry of Education, Southwest Forestry UniversityKey Laboratory for Forest Resources Conservation and Utilization in the Southwest Mountains of China, Ministry of Education, Southwest Forestry UniversityThe First Affiliated Hospital of Yunnan University of Traditional Chinese MedicineNew York College of Traditional Chinese MedicineAbstract Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions.https://doi.org/10.1186/s12943-023-01904-wLeukemiaLymphomaPTCLNHLT-ALLALCL |
| spellingShingle | Yunpeng Luan Xiang Li Yunqi Luan Junyu Luo Qinzuo Dong Shili Ye Yuejin Li Yanmei Li Lu Jia Jun Yang Dong-Hua Yang Therapeutic challenges in peripheral T-cell lymphoma Molecular Cancer Leukemia Lymphoma PTCL NHL T-ALL ALCL |
| title | Therapeutic challenges in peripheral T-cell lymphoma |
| title_full | Therapeutic challenges in peripheral T-cell lymphoma |
| title_fullStr | Therapeutic challenges in peripheral T-cell lymphoma |
| title_full_unstemmed | Therapeutic challenges in peripheral T-cell lymphoma |
| title_short | Therapeutic challenges in peripheral T-cell lymphoma |
| title_sort | therapeutic challenges in peripheral t cell lymphoma |
| topic | Leukemia Lymphoma PTCL NHL T-ALL ALCL |
| url | https://doi.org/10.1186/s12943-023-01904-w |
| work_keys_str_mv | AT yunpengluan therapeuticchallengesinperipheraltcelllymphoma AT xiangli therapeuticchallengesinperipheraltcelllymphoma AT yunqiluan therapeuticchallengesinperipheraltcelllymphoma AT junyuluo therapeuticchallengesinperipheraltcelllymphoma AT qinzuodong therapeuticchallengesinperipheraltcelllymphoma AT shiliye therapeuticchallengesinperipheraltcelllymphoma AT yuejinli therapeuticchallengesinperipheraltcelllymphoma AT yanmeili therapeuticchallengesinperipheraltcelllymphoma AT lujia therapeuticchallengesinperipheraltcelllymphoma AT junyang therapeuticchallengesinperipheraltcelllymphoma AT donghuayang therapeuticchallengesinperipheraltcelllymphoma |